Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 48Active not recruiting 26Terminated 22Recruiting 18Withdrawn 7Unknown 7Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 15Gastrointestinal 15Head & Neck 9Genitourinary 9Breast 9Gynecologic 7CNS 6Dermatologic 4Lymphoid 2Tumor-Agnostic 1Plasma cell 1Other solid neoplasm 1

Conditions

Hodgkin Disease 2

Interventions

Cyclophosphamide 30Rituximab 23zanubrutinib 18fludarabine 14Vincristine 14venetoclax 13Prednisone 13blinatumomab 12Magnetic Resonance Spectroscopy 12Specimen Handling 11Doxorubicin 11obinutuzumab 10Bendamustine Hydrochloride 10Lenalidomide 9Dexamethasone 8polatuzumab vedotin 7glofitamab 7Methotrexate 7Radiotherapy 6Prednisolone 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Cytarabine 6Biopsy 6pirtobrutinib 5pegaspargase 5Immunotherapy, Adoptive 5tislelizumab 4tafasitamab 4selinexor 4orelabrutinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × pembrolizumab × Lymphoid × Clear all
NCT07021989 2026-06-04

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

University of California, San Francisco

Phase 2 Not yet recruiting
38 enrolled
Lymphoid

Hodgkin Disease

NCT06045195 2025-04-06

Pembro-FLASH

University of Cologne

Phase 2 Not yet recruiting
40 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡